Trial Profile

A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 24 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alrizomadlin (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Appendiceal cancer; Carcinoma; Liposarcoma; Lung cancer; Malignant melanoma; Nerve sheath neoplasms; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Urogenital cancer; Uveal melanoma
Focus Adverse reactions; Therapeutic Use
Acronyms Keynote MK-3475-B66
Sponsors Ascentage Pharma

Most Recent Events

19 Jul 2024 Planned number of patients changed from 224 to 230.
30 Jan 2024 Planned End Date changed from 30 Mar 2024 to 30 Mar 2025.
30 Jan 2024 Planned primary completion date changed from 30 Dec 2023 to 30 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com